The market for oral anticoagulants has advanced significantly since warfarin was essentially the lone option. Still, in some cases, the use of improved direct oral anticoagulants (DOACs) can provoke ...

August 13, 2010 (Miami, Florida) — Researchers believe they may have found a truly reversible anticoagulant system to control bleeding during PCI that consists of one agent to anticoagulate and ...

Please provide your email address to receive an email when new articles are posted on . Anticoagulants are one of the most commonly prescribed medication classes, and the utilization of these agents ...

Please provide your email address to receive an email when new articles are posted on . AIMS65 score predicted mortality and rebleeding for patients on anticoagulants with gastrointestinal bleeding.

In the acute phase of oral anticoagulation-associated intracerebral hemorrhage (OAC-ICH), two factors can protect against hematoma enlargement: getting the international normalized ratio (INR) below 1 ...

About The Study: In hospitals participating in Get With The Guidelines–Stroke, earlier anticoagulation reversal was associated with improved survival for patients with intracerebral hemorrhage. These ...

Shaanxi Micot Technology Co. Ltd. has described theophylline derivatives acting as anticoagulant reversal agents reported to be useful for the treatment of hemorrhagic disorders.

PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...

LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised ...

Every day, surgeons are faced with the task of ensuring that their patients do not experience blood clotting during the invasive procedure. Clots can be potentially life-threatening, since they can ...

WILMINGTON, Del.--(BUSINESS WIRE)--ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including ...

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia that significantly elevates the risk of thromboembolic events, most notably ischaemic stroke. Anticoagulation therapy has long been a ...